Diabetes mellitus (DM) is a worldwide epidemic. Its prevalence is rapidly increasing in both
developing and developed countries. Coronary heart disease (CHD) is highly prevalent and …

Peroxisome proliferator-activated receptors (PPARs) are lipid-activated transcription factors
that regulate lipid and lipoprotein metabolism, glucose homeostasis and inflammation. The …

Background In patients with type 2 diabetes mellitus, all therapeutic options should be
evaluated for their effect on cardiovascular risk factors, in addition to glycemic control. We …

OBJECTIVE—Thiazolidinediones (TZDs), a class of insulin-sensitizing agents used clinically
to treat type 2 diabetes, are also antiatherogenic. This study was designed to elucidate the …

OBJECTIVE—Despite the popularity of coronary stenting in coronary artery disease (CAD),
restenosis remains a challenging clinical problem. This study evaluated the efficacy of …

Although diabetic patients represent approximately one-quarter of all those undergoing
revascularization, their outcomes after revascularization are usually worse compared with …

IN BRIEF The paradigms for oral pharmacological therapy in type 2 diabetes are shifting as
we attain new insights into the optimal metabolic control in our patients. Each drug category …

Peroxisome proliferator-activated receptor γ (PPARγ) is a ligand-activated transcription
factor belonging to the nuclear hormone receptor superfamily. PPARγ is expressed by …

Background—Restenosis requiring reintervention limits the long-term success after coronary
stent implantation. Thiazolidinediones, like pioglitazone or rosiglitazone, are oral …

The thiazolidinediones typically reduce hemoglobin A1c by 1% to 2% compared with
placebo, similar to effects observed with metformin and sulfonylureas in head-to-head …